Previous 10 | Next 10 |
Cannabics Pharmaceuticals receives "Intention to Grant a European Patent" notice for its System and Method for High Throughput Screening of Cancer Cells patent application PR Newswire TEL AVIV, Israel and BETHESDA, Maryland, Oct. 27, 2020 TEL AVIV , Israel a...
Cannabics Pharmaceuticals Prepares to Submit the FDA with a pre-IND Meeting Request for its Proprietary Colon Cancer Drug Candidate, CANNABICS™ RCC-33 PR Newswire TEL AVIV, Israel and BETHESDA, Md., Oct. 21, 2020 TEL AVIV , Israel and BETHESDA,...
TEL AVIV , Israel and BETHESDA, Maryland , Aug. 20, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it is establishing a dedicated division for the deve...
TEL AVIV , Israel and BETHESDA, Md., Aug. 5, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Dr. Dana Ben-Ami Shor to its Scienti...
TEL AVIV , Israel and BETHESDA, Maryland , July 14, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has initiated activities to penetrate European ma...
TEL AVIV , Israel and BETHESDA, Maryland , June 16, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Dr. Erez Scapa to its Scient...
TEL AVIV , Israel and BETHESDA, Maryland, June 10, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has signed a Memorandum Of Understand...
TEL AVIV, Israel and BETHESDA, Maryland , May 26, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that the Israeli government has granted final approval for the expor...
TEL AVIV , Israel and BETHESDA, Maryland , May 6, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has filed a Provisional Patent Application with the...
TEL AVIV , Israel and BETHESDA, Maryland , April 27, 2020 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has appointed Prof. Zamir Halpern to i...
News, Short Squeeze, Breakout and More Instantly...
Cannabics Pharmaceuticals Inc Company Name:
CNBX Stock Symbol:
OTCMKTS Market:
Cannabics Pharmaceuticals Inc Website:
CNBX Pharmaceuticals Inc (CNBX) is expected to report for Q1 2003
CNBX to Enter the Cancer Immunotherapy Market After Acquiring a Controlling Interest in TaGeza Biopharma PR Newswire REHOVOT, Israel and BETHESDA, MD , Nov. 8, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader i...
CNBX Files New PCT Patent Application For Cannabinoids-Based Neoadjuvant Cancer Therapy PR Newswire REHOVOT, Israel and BETHESDA, MD. , Oct. 18, 2022 /PRNewswire/ -- CNBX Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of...